Description: Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Home Page: ventyxbio.com
VTYX Technical Analysis
662 Encinitas Boulevard
Encinitas,
CA
92024
United States
Phone:
760-593-4832
Officers
| Name | Title |
|---|---|
| Dr. Sheila K. Gujrathi M.D. | Exec. Chair |
| Dr. Raju S. Mohan Ph.D. | Founder, CEO & Director |
| Dr. John M. Nuss Ph.D. | Chief Scientific Officer |
| Mr. Christopher W. Krueger J.D., MBA | Chief Bus. Officer |
| Prof. William J. Sandborn M.D., Ph.D. | Pres & Chief Medical Officer |
| Dr. Martin Douglas Auster M.D. | Chief Financial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.015 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 44 |